6.
Wilson A
. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS One. 2011; 6(2):e16976.
PMC: 3038871.
DOI: 10.1371/journal.pone.0016976.
View
7.
Rouamba T, Nakanabo-Diallo S, Derra K, Rouamba E, Kazienga A, Inoue Y
. Socioeconomic and environmental factors associated with malaria hotspots in the Nanoro demographic surveillance area, Burkina Faso. BMC Public Health. 2019; 19(1):249.
PMC: 6396465.
DOI: 10.1186/s12889-019-6565-z.
View
8.
Tinto H, Ouedraogo J, Zongo I, Van Overmeir C, Van Marck E, Guiguemde T
. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. Am J Trop Med Hyg. 2007; 76(4):608-13.
View
9.
Gansane A, Moriarty L, Menard D, Yerbanga I, Ouedraogo E, Sondo P
. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017-2018. Malar J. 2021; 20(1):48.
PMC: 7816451.
DOI: 10.1186/s12936-021-03585-6.
View
10.
Sisowath C, Petersen I, Veiga M, Martensson A, Premji Z, Bjorkman A
. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009; 199(5):750-7.
PMC: 2718568.
DOI: 10.1086/596738.
View
11.
Veiga M, Dhingra S, Henrich P, Straimer J, Gnadig N, Uhlemann A
. Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat Commun. 2016; 7:11553.
PMC: 4873939.
DOI: 10.1038/ncomms11553.
View
12.
Some A, Zongo I, Compaore Y, Sakande S, Nosten F, Ouedraogo J
. Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother. 2014; 58(7):3660-5.
PMC: 4068591.
DOI: 10.1128/AAC.02406-14.
View
13.
Ringwald P
. [Current antimalarial drugs: resistance and new strategies]. Bull Acad Natl Med. 2008; 191(7):1273-84.
View
14.
Menard D, Dondorp A
. Antimalarial Drug Resistance: A Threat to Malaria Elimination. Cold Spring Harb Perspect Med. 2017; 7(7).
PMC: 5495053.
DOI: 10.1101/cshperspect.a025619.
View
15.
Konate A, Yaro J, Ouedraogo A, Diarra A, Gansane A, Soulama I
. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011; 8(2):e1000408.
PMC: 3032552.
DOI: 10.1371/journal.pmed.1000408.
View
16.
Preechapornkul P, Imwong M, Chotivanich K, Pongtavornpinyo W, Dondorp A, Day N
. Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness. Antimicrob Agents Chemother. 2009; 53(4):1509-15.
PMC: 2663078.
DOI: 10.1128/AAC.00241-08.
View
17.
Cuu G, Asua V, Tukwasibwe S, Nsobya S, Nanteza A, Kimuda M
. Associations between Aminoquinoline Resistance Genotypes and Clinical Presentations of Plasmodium falciparum Infection in Uganda. Antimicrob Agents Chemother. 2020; 64(10).
PMC: 7508615.
DOI: 10.1128/AAC.00721-20.
View
18.
Ouoba J, Lankoande-Haro S, Fofana S, Nacoulma A, Kabore L, Sombie I
. . Sante Publique. 2024; 35(5):121-132.
DOI: 10.3917/spub.235.0121.
View
19.
Sondo P, Tahita M, Rouamba T, Derra K, Kabore B, Compaore C
. Assessment of a combined strategy of seasonal malaria chemoprevention and supplementation with vitamin A, zinc and Plumpy'Doz™ to prevent malaria and malnutrition in children under 5 years old in Burkina Faso: a randomized open-label trial.... Trials. 2021; 22(1):360.
PMC: 8142067.
DOI: 10.1186/s13063-021-05320-7.
View
20.
Natama H, Rovira-Vallbona E, Some M, Zango S, Sorgho H, Guetens P
. Malaria incidence and prevalence during the first year of life in Nanoro, Burkina Faso: a birth-cohort study. Malar J. 2018; 17(1):163.
PMC: 5898041.
DOI: 10.1186/s12936-018-2315-4.
View